To get a better understanding of the pathophysiology of dosage-reducing mutations in Alzheimer’s risk gene ABCA7, we studied nine different CSF biomarkers, representing several AD-associated pathways in our study cohort. Here, ABCA7 is linked to Alzheimer disease.